Revelation Biosciences, Inc. REVB
3.56 USD -0.56 (-13.54%)
At closeNov 5, 2026, 4:00 PM EST
3.62 +0.06 +1.69%
After hours · Nov 5, 4:00 PM ET
3.43 Day range 3.76
3.08 52-week range 40.60
- YTD
- +11.25%
- 1 year
- -17.59%
- Market cap
- 2.03M
- EPS (ttm)
- 32.20
- Shares out
- 8.36M
- P/E ratio
- 0.11
- Forward P/E
- -0.13
- YTD return
- +11.25%
- 1-year return
- -17.59%
- Volume
- 15.12K
- Avg volume
- 11.37K
- Open
- 3.76
- Previous close
- 4.12
- Day's range
- 3.43 – 3.76
- 52-week range
- 3.08 – 40.60
- Price target
- 12.75 (+258.1%)
- Earnings date
- Aug 9, 2024
5D -0.23 (-6.07%)
Key statistics
- Enterprise value
- -5.27M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.49
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -6.49M
- Total cash
- 6.54M
- Total debt
- 0
- Return on equity
- -270.02%
- Short % of float
- 2.93%
- 50-day average
- 0.7149
- 200-day average
- 1.49
Analyst view
Price target (mean) 12.75 +258.1% upside
Now 3.56
- Target (low)
- 5.50
- Target (mean)
- 12.75
- Target (high)
- 20.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 9, 2024
Expected Aug 9, 2024. Consensus EPS estimate -0.43.
Financials — quick view
REVB Revenue — quarterly 0
REVB Net income — quarterly -3.32M
REVB EPS — quarterly -6.10
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -2.84 | -0.84 | +2.00 | +70.42% |
| Aug 9, 2024 | Jun 1, 2024 | -1.81 | -1.54 | +0.27 | +14.92% |
| Aug 9, 2024 | Jun 1, 2024 | -1.81 | — | — | — |
| May 10, 2024 | Mar 1, 2024 | -5.39 | -2.46 | +2.93 | +54.36% |
| May 10, 2024 | Mar 1, 2024 | -5.39 | — | — | — |
| Mar 22, 2024 | Dec 1, 2023 | -10.94 | -8.33 | +2.61 | +23.86% |
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- revbiosciences.com
News
Revelation Biosciences Q3 EPS $(5.92) Beats $(6.16) Estimate 
Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026 
Revelation Biosciences Announces 1-For-7 Reverse Stock Split, Effective Oct. 20 
Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026 
12 Health Care Stocks Moving In Thursday's After-Market Session - Revelation Biosciences Selected Avance Clinical To Serve As CRO For Phase 2/3 Adaptive-Design TITAN Study For Evaluating Gemini In Patients With Acute Kidney Injury
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study 
Revelation Biosciences Q2 EPS $(0.87) Beats $(0.88) Estimate 
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026 
Revelation Biosciences Cites Independent Market Assessment Indicating A $94B Total Addressable Market For Its Gemini Kidney Treatment
Your note
Sign in to keep a note on REVB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| TIDMARSH GEORGE F | Director | Sale | Dec 7, 2023 | 42,096 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sabby Management, LLC | 0.51% | 42,226 | 12.77K | Sep 29, 2024 |
| UBS Group AG | 0.49% | 40,945 | 12.38K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.16% | 13,258 | 4.01K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.03% | 2,539 | 767 | Sep 29, 2024 |
| Pom Investment Strategies, LLC | 0.00% | 1 | 0 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 29 | 8 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.10% | 8,022 | 2.42K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.04% | 2,942 | 889 | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 201 | 60 | Sep 29, 2024 |